{
    "organizations": [],
    "uuid": "ae758b1904b4765f181dfb81365c70f188d5f9d1",
    "author": "",
    "url": "https://www.reuters.com/article/brief-q-state-biosciences-says-entered-s/brief-q-state-biosciences-says-entered-strategic-collaboration-with-vertex-pharmaceuticals-idUSFWN1RH0EY",
    "ord_in_thread": 0,
    "title": "BRIEF-Q-State Biosciences Says Entered Strategic Collaboration With Vertex Pharmaceuticals",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 4, 2018 / 12:12 PM / in 12 minutes BRIEF-Q-State Biosciences Says Entered Strategic Collaboration With Vertex Pharmaceuticals Reuters Staff \nApril 4 (Reuters) - Vertex Pharmaceuticals Inc: * COâ€™S NOVEL OPTOPATCH PLATFORM \n* PER TERMS OF DEAL, CO TO RECEIVE UPFRONT & RESEARCH SUPPORT, ELIGIBLE TO RECEIVE RESEARCH, DEVELOPMENT & SALES MILESTONES * STATE WILL ALSO RECEIVE ROYALTIES ON DRUG SALES \n* CO, VERTEX PHARMACEUTICALS WILL COLLABORATE FOR AT LEAST TWO YEARS \n* VERTEX IS RESPONSIBLE FOR ALL DEVELOPMENT AND COMMERCIALIZATION ACTIVITIES RESULTING FROM COLLABORATION Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)",
    "published": "2018-04-04T15:11:00.000+03:00",
    "crawled": "2018-04-04T15:39:43.006+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "minute",
        "bioscience",
        "say",
        "entered",
        "strategic",
        "collaboration",
        "vertex",
        "pharmaceutical",
        "reuters",
        "staff",
        "april",
        "reuters",
        "vertex",
        "pharmaceutical",
        "inc",
        "co",
        "novel",
        "optopatch",
        "platform",
        "per",
        "term",
        "deal",
        "co",
        "receive",
        "upfront",
        "research",
        "support",
        "eligible",
        "receive",
        "research",
        "development",
        "sale",
        "milestone",
        "state",
        "also",
        "receive",
        "royalty",
        "drug",
        "sale",
        "co",
        "vertex",
        "pharmaceutical",
        "collaborate",
        "least",
        "two",
        "year",
        "vertex",
        "responsible",
        "development",
        "commercialization",
        "activity",
        "resulting",
        "collaboration",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}